TORONTO, Nov. 25, 2024 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that the final tranche of the unsecured convertible debentures (the "Convertible Debentures") originally issued by the Company on November 22, 2019, have been converted into common shares ("Common Shares") at a price of C$3.00 per Common Share pursuant to the terms of the Convertible Debentures.

As part of a private placement financing announced on September 30, 2019, CareRx issued $27,500,000 aggregate principal amount of 8.25% unsecured Convertible Debentures to Yorkville Asset Management, Inc. and certain shareholders and directors of the Company. Each Convertible Debenture was convertible into Common Shares at the option of the holder at a conversion price of $3.00 per Common Share (the "Conversion Price"). In addition, the Convertible Debentures had a mandatory conversion feature such that 25% of the outstanding original principal amount of the Convertible Debentures automatically converted into Common Shares at the Conversion Price at the beginning of years two, three, four and five following their issue date. The Convertible Debentures have now been extinguished in full.

Continued Expansion of Adjusted EBITDA and EBITDA Margin

TORONTO, Nov. 8, 2024 /CNW/ - CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today reported its financial results for the third quarter ended September 30, 2024.

"Over the past 18 months, we have been deeply committed to strengthening our business by modernizing our operating platform, reducing net debt, enhancing service levels, and further solidifying our position as the leading pharmacy services provider to the seniors living sector," said Puneet Khanna, President and Chief Executive Officer of CareRx. "Our disciplined approach to resource allocation, and prioritizing profitable beds, have resulted in five consecutive quarters of EBITDA growth. With an enhanced operating platform, a strong growth pipeline and confirmed bed wins for 2025, we are now well-positioned to capitalize on the next wave of growth in the senior care sector."

TORONTO, Oct. 31, 2024 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced it will host a conference call, including a slide presentation, to discuss its third quarter 2024 financial results on Friday, November 8, 2024, at 8:30 a.m. Eastern Time (ET). The Company expects to report its third quarter 2024 financial results via news release at approximately 7:00 a.m. ET on Friday, November 8, 2024.

Telephone Dial-In Access Information

To join the conference call without operator assistance, you may register and enter your phone number at https://emportal.ink/4gXoyoU to receive an instant automated call back.

TORONTO, Oct. 1, 2024 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that it will be opening a new state-of-the-art pharmacy in North Burnaby, British Columbia.

This new pharmacy fulfillment centre is designed to enhance service delivery for the homes and residents serviced by CareRx throughout the B.C. lower mainland, while improving the employee experience, through optimized workflows, streamlined operations and leading-edge medication packaging technology. Notably, this location will utilize an advanced high-volume medication packaging technology, allowing for the processing of significantly higher prescription volumes, while enhancing safety and reducing waste.

TORONTO, Sept. 5, 2024 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024.

Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.

TORONTO, Sept. 3, 2024 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that the Toronto Stock Exchange (the "TSX") has approved the Company's normal course issuer bid (the "NCIB") to purchase for cancellation up to 1,500,000 of its common shares ("Shares"), representing approximately 2.5% of its 60,075,433 issued and outstanding Shares as at August 27, 2024.

It is expected that the NCIB will begin on September 7, 2024 and will end on September 6, 2025. Daily purchases on the TSX under the NCIB will be limited to 3,521 Shares, other than purchases made pursuant to the block purchase exception, being 25% of the average daily trading volume on the TSX for the six months ending July 31, 2024. The actual number of Shares to be purchased, and the timing of any such purchases, will be determined by the Company, subject to the applicable rules and policies of the TSX. All Shares acquired will be cancelled.

Delivers Continued Adjusted EBITDA Growth

TORONTO, Aug. 8, 2024 /CNW/ - CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today reported its financial results for the second quarter ended June 30, 2024.

"Our second quarter results illustrate steady progress in the strengthening of our operational platform," said Puneet Khanna, President & Chief Executive Officer of CareRx. "We remain focused on increasing productivity, driving efficiencies and managing cost pressures that continue to impact the broader healthcare sector. This process will ensure we are well positioned to respond immediately when growth opportunities present themselves, and we intend to capitalize on our leadership position to generate value for our shareholders, stakeholders and customers by providing exceptional pharmacy services through the long-term expansion cycle of the seniors living sector."